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Interferons (IFNs) play a central role in immunity and emerging evidence suggests that IFN-signalling
coordinately regulates sterol biosynthesis in macrophages, via Sterol Regulatory Element-Binding
Protein (SREBP) dependent and independent pathways. However, the precise mechanisms and kinetic
steps by which IFN controls sterol biosynthesis are as yet not fully understood. Here, we elucidate the
molecular circuitry governing how IFN controls the ﬁrst regulated step in the mevalonate-sterol pathway,
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), through the synthesis of 25-Hydroxycholesterol
(25-HC) from cholesterol by the IFN-inducible Cholesterol-25-Hydroxylase (CH25H). We show for the
ﬁrst 30-min of IFN stimulation of macrophages the rate of de novo synthesis of the Ch25h transcript is
markedly increased but by 120-min becomes transcriptionally curtailed, coincident with induction of
the Activating Transcription Factor 3 (ATF3) repressor. We demonstrate ATF3 induction by Toll-like
receptors is strictly dependent on IFN-signalling. While the SREBP-pathway dependent rates of de novo
transcription of Hmgcr are relatively unchanged in the ﬁrst 90-min of IFN treatment, we ﬁnd HMGCR
enzyme levels undergo a rapid proteasomal-mediated degradation, deﬁning a previously unappreciated
SREBP-independent mechanism for IFN-action. These events precede a sustained marked reduction in
Hmgcr RNA levels involving SREBP-dependent mechanisms. We demonstrate that HMGCR
proteasomal-degradation by IFN strictly requires the synthesis of endogenous 25-HC and functionally
couples HMGCR to CH25H to coordinately suppress sterol biosynthesis. In conclusion, we quantitatively
delineate proteomic and transcriptional levels of IFN-mediated control of HMGCR, the primary enzymatic
step of the mevalonate-sterol biosynthesis pathway, providing a foundational framework for mathemati-
cally modelling the therapeutic outcome of immune-metabolic pathways.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
3-Hydroxy-3-methylglutaryl-CoA reductase (HMGCR) operates
as an important regulated step enzyme in the mevalonate-sterol
biosynthesis pathway, which is responsible for the production of
cholesterol and isoprenoid products [1,2]. HMGCR is also animportant therapeutic target for a class of inhibitory drugs, known
as statins, which are prescribed to reduce cholesterol levels in the
serum. Statin treatment reduces cholesterol but leads to a compen-
satory increase of HMGCR via the SREBP pathway (schematically
shown in Fig. 6) and which also increases the level of low-density
lipoprotein (LDL) receptors, leading to reduction in plasmaprotein;
d serum;
dendritic
220 H. Lu et al. / Steroids 99 (2015) 219–229cholesterol levels [1]. Given the importance of HMGCR in the
biosynthesis of sterols, HMGCR is subject to stringent and multiple
regulatory feedback mechanisms.
Regulation of HMGCR at the transcriptional level is exquisitely
sensitive to feedback control mediated by the Golgi-nuclear shut-
tling of the master transcriptional regulator of the sterol pathway,
SREBP2 [3–5]. Under conditions of high intra-cellular sterol levels,
excess oxysterols and cholesterol bind to INSIG and SCAP proteins,
respectively. This blocks transport of mature SREBP2 from the ER
to the golgi, where cleavage of SREBP2 and release of the active
transcription factor would normally take place [6–9]. Under
sterol-limiting conditions, sterol binding to INSIG and SREBP cleav-
age activating protein (SCAP) does not occur and SCAP becomes
free to escort SREBP2 from the ER to the golgi, where SREBP2
undergoes proteolytic cleavage [10–14] to generate an N-terminal
domain of SREBP2 which is released into the nucleus to activate
multiple sterol biosynthesis related genes, including Hmgcr [15].
Regulation of HMGCR at the post-transcriptional and post-
translational level operates independently of the SREBP regulatory
pathway and represents an important mechanism for regulating
HMGCR in response to changing sterol levels. Post-translational
regulation is exerted by oxysterol-dependent degradation, via an
INSIG dependent ER-associated protein degradation (ERAD) sys-
tem, involving an ubiquitin-proteasome degradation pathway
[16,17]. Under sterol depleted conditions, the half-life of HMGCR
is approximately 12 h. However, in the presence of excess sterols,
degradation of HMGCR by the ERAD mechanism results in a half-
life of about 40 min [18]. This highly sensitive and responsive pro-
teomic mechanism contrasts with the relatively slow transcrip-
tional regulation mediated by the SREBP pathway which takes
several hours to exert an effect on HMGCR protein levels [19].
It is well established that the oxysterol, 25-HC, which is synthe-
sised from cholesterol by the enzyme CH25H, has a potent ability
to block cholesterol biosynthesis through INSIG induced ubiq-
uitination and proteasomal degradation of HMGCR [4,20,21] and
also by blocking ER translocation of SREBP2 [22]. However, 25-
HC has been shown not to play a major role in cholesterol home-
ostasis but instead has emerged to have key immune modulatory
functions [1,23]. We have been the ﬁrst to report that HMGCR
levels and sterol biosynthesis are suppressed by interferon (IFN)
and in infected macrophages the reduction of HMGCR is strictly
dependent on IFN-induced signalling [24]. Moreover, in this
connection 25-HC has also been shown to have a range of effects
on immune related host defence systems, including suppressing
the differentiation of human monocytes [25], decreasing
immunoglobulin A production [26], promoting immune cell guid-
ance [23], moderating inﬂammasome activity [27] and amplifying
inﬂammatory signalling via AP-1 [28]. Park and Scott reported that
the production of CH25H is stimulated by TLR activation in macro-
phages and DCs [29]. In later studies, we and other laboratories
demonstrated that the IFN-mediated production of 25-HC has
broad anti-viral and immune modulatory activities [27,28,30,31].
It has also been reported by many groups including our own stud-
ies that RNA-interference (RNAi) mediated knockdown of HMGCR
protein levels and pharmaceutical inhibition of HMGCR activity
can suppress viral infectivity and growth [24,32–34]. In addition,
it is worth noting that HMGCR inhibitors (statins) also have
immune modulatory effects [35]. Collectively, these ﬁndings point
to an emerging role for HMGCR as a control point in the regulation
of immunomodulatory and host defence mechanisms. However,
the precise role of 25-HC in the immune system has not been fully
deﬁned. Moreover, roles for SREBP-independent mechanisms for
anti-viral and anti-inﬂammatory effects have yet to be deﬁned.
In this study, we examine further the regulation of HMGCR fol-
lowing early innate immune stimulation by IFN-c. We report for
the ﬁrst time systematic quantitative analyses of the IFNregulatory circuit in macrophages for CH25H, its repressor ATF3,
and how they couple to HMGCR, revealing a previously unap-
preciated role for the IFN-mediated degradation of HMGCR enzyme
levels that is shown to be critically dependent on the de novo syn-
thesis of 25-HC. Overall, this study contributes to the dissection of
the mechanisms underlying the regulation of HMGCR as an emerg-
ing effector target during innate-immune-metabolic signalling and
provides a foundation for future modelling of pathway feedback
control.
2. Experimental
2.1. Reagents and media
25-HC and mevastatin were purchased from Sigma (Sigma-
Aldrich, UK). MG132 (Z-Leu-Leu-Leu-al) (CAS number: 133407-
82-6) was purchased from Cambridge Bioscience. Murine recombi-
nant IFN-c was purchased from Perbio Science or Life Technology
(PMC4033). Medium A: DMEM/F12 with GlutaMAX (Gibco, Life
technologies) supplemented with 10% (v/v) fetal bovine serum
(FBS) (Gibco, Life technologies), 10% (v/v) L929 containing col-
ony-stimulating factor 1 (Csf1) and Penicillin/streptomycin (PS)
(Gibco, Life technologies); Medium B: DMEM/F12 with
GlutaMAX supplemented with 3% (v/v) lipoprotein depleted serum
(LPDS) (Sigma), 10% (v/v) L929 containing Csf1 and PS;Medium C:
DMEM/F12 with GlutaMAX supplemented with 3% (v/v) LPDS,
0.01 lM mevastatin, 10% (v/v) L929 containing Csf1 and PS. The
following antibodies were used: monoclonal mouse anti-HMGCR
(C-1, Santa Cruz Biotechnology), rabbit anti-b-actin (4967, Cell
Signaling) and rabbit anti-b-tubulin (ab6046, Abcam).
2.2. Primary bone marrow derived macrophage (BMDM) culture
generation
Wild-type BMDMs were derived from the femur and tibia iso-
lated from C57BL/6 mice as previously described [24,30]. Ch25h/
BMDMs were derived from the femur and tibia isolated from
B6.129S6-Ch25htm1Rus/J mice (The Jackson Laboratory, UK) and
grown in Medium A. Ifnb/ mice were from the Institute of
Animal Breeding and Genetics (Veterinary University of Vienna).
All procedures were carried out under project and personal licences
approved by the Secretary of State for the Home Ofﬁce, under the
United Kingdoms 1986 Animals (Scientiﬁc Procedures) Act and the
Local Ethical Review Committee at Edinburgh University. All cul-
tures are routinely tested to ensure they are free of mycoplasma
and endotoxin contamination.
2.3. Experimental treatment conditions
BMDMs were grown in 24-well plates with Medium A. For the
dose titration of mevastatin, cells were treated overnight with
Medium B containing various concentrations of mevastatin. For
the dose titration of 25-HC, cells were treated as the ﬁgure legend
described. The cells were then harvested for western blot analysis.
For time course experiments, Prior to the experiment, IFN-c stock
was diluted as described [24]. Culture medium was aspirated from
24-well plates and 1 mL of Medium C containing IFN-c (5 ng/mL)
was added to wells at 1.5-h, 4-h and 9-h time points, respectively.
Meanwhile, a parallel experiment, where the cells were treated
with 25-HC (2.5 lM), was performed at the same time. The cells
were harvested for western blot analysis. For the measurement
of HMGCR protein levels with proteasome inhibitor MG132,
BMDMs were pre-treated with Medium B containing MG132
(20 lM) for an hour; and then treated with Medium C plus
MG132 (20 lM) containing IFN-c (5 ng/mL) or 25-HC (2.5 lM),
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HMGCR levels were determined by western blot analysis.2.4. qRT-PCR analysis
QIAGEN Rneasy Plus Mini Kit (QIAGEN, Germany) was used to
purify total RNA. The qScript One-Step Fast qRT-PCR kit, Low
ROX (Quanta BioSciences, USA), Taqman probe/primer Hmgcr,
Atf3, Ch25h, Irf1 and Gapdh (Life technologies, UK) were used for
the qRT-PCR measurement. qRT-PCR was undertaken according
to manufactures instructions.2.5. Western blot analysis
After treatments, cells were lysed directly in wells by adding
100 lL of RIPA lysis buffer (9806, Cell Signaling) supplemented
with protease cocktail (Complete Protease Inhibitor Cocktail
Tablets, Roche) and 1 mM Phenylmethanesulfonyl ﬂuoride
(Sigma). Plates were incubated on ice for 20 min. Protein concen-
trations of whole-cell lysate fractions were then determined using
the BCA Protein Assay Reagent kit (Thermo Scientiﬁc) according to
manufacturers instructions. Prior to SDS–PAGE, whole-cell lysates
were mixed with 2X Laemmli sample buffer (Sigma) and incubated
at 50 C for 10 min. Thereafter, an equal amount of protein was
subjected to 8% SDS-PAGE, after which proteins were transferred
to Hybond ECL Nitrocellulose membranes (Amersham). The mem-
branes were blocked with 5% skimmed milk (Sigma), probed with
speciﬁc primary antibodies overnight at 4 C, washed with PBST
(Phosphate Buffered Saline with Tween 20), incubated with HRP-
conjugated secondary antibodies (Cell Signaling) at room tempera-
ture for 1 h. The membranes were then re-washed with PBST and
bands were visualised by Hyperﬁlm ECL (Amersham) or Odyssey
Fc Dual-Mode Imaging System (Li-COR Biosciences) with
ClarityTM Western ECL Substrate (BIO-RAD). Image Studio Lite (Li-
COR Biosciences) was used to analyse the bands.2.6. BMDM de novo RNA labelling, isolation and microarray analysis
2.6.1. Time course analysis of RNA synthesis and half-life in Control-
treated or IFN-c-treated BMDMs
To enable a simultaneous analysis of RNA synthesis, abundance
and decay, BMDMs were control treated or treated with IFN-c at a
concentration of 5 ng/mL. These treatments were then followed by
16 successive cycles of 4-thiouridine addition to the BMDM cul-
tures and transcriptional termination at 30 min intervals until
the end of an 8-h time course. 4-Thiouridine (Sigma) labelling in
these experiments was undertaken as described by Dölken et al.
[36].
Total RNA was then isolated using an RNeasy Midi kit (Qiagen)
according to manufacturers instructions, quantitated using a
Nanodrop (Thermo Scientiﬁc) and integrity was conﬁrmed using
an Agilent Bioanalyser (Agilent UK). Newly transcribed RNA
(ntRNA) was then isolated and again quantitated using a
Nanodrop.2.6.2. RNA labelling for time-course microarray analysis
Processing of 100 ng of total RNA samples (8 1 h for control
treated and 8 1 h for IFN-c treated = 16 in total) and ntRNA sam-
ples (16 30 min for control treated and 16 30 min for IFN-c trea-
ted = 32 in total) for hybridisation to Affymetrix Mouse Gene 1.0 ST
arrays was undertaken according to manufacturers instructions
(Affymetrix). Hybridisation, washing, staining and scanning of
the arrays were also undertaken following standard Affymetrix
protocols.2.6.3. Data analysis for microarray time-course
After scanning and data capture, open-source R based software
‘‘Bioconductor’’ was used to implement all quality control and sta-
tistical analyses.
The RMA method was then used for normalisation, background
correction, and probe set summation [37]. To reduce the dataset
for further analysis and enrich for reliably detected genes, values
for median and 2 the Median Absolute Deviation (2MAD) for
negative control probesets were calculated for each array.
Intensity values for each probe on each total RNA array were then
compared with their array speciﬁc 2MAD value and were
retained if the intensity was equal to or greater than this value.
After ﬁltering and removal of all designated Affymetrix control
probesets, 12,472 probes were retained for statistical analyses.
Since conventional clustering algorithms do not typically assign
signiﬁcance to differential expression of two conditions over time
(on an individual gene basis) the MaSigPro algorithm was used
[38]. Using this method, 2086 (ntRNA) or 4482 (total RNA) probes
with notable differential proﬁles of expression across the 8 h of
IFN-c stimulation were identiﬁed.
2.6.4. Microarray analysis of total, pre-existing and newly transcribed
RNA in resting BMDMs
Using the protocol of Dölken et al. [36]for de novo RNA labelling
and isolation, we used Affymetrix Gene STv1.0 microarrays to anal-
yse total RNA abundance in resting BMDMs at t = 0 h and total,
newly transcribed (labelled) and pre-existing (unlabelled) RNA at
t = 1 h. This was completed in triplicate. To enrich for reliably
detected genes, values for median and 2 the Median Absolute
Deviation (2MAD) for negative control probe-sets were calcu-
lated for each array. Intensity values for each probe on each total
RNA array were then compared with their array speciﬁc 2MAD
value and were retained if the intensity was equal to or greater
than this value. After ﬁltering and removal of all designated
Affymetrix control probe-sets, 5826 probes were classiﬁed as
detected on all arrays. Mean values for the total RNA, newly tran-
scribed RNA and pre-existing RNA abundance measurements were
then calculated from triplicate measurements and this data was
used for the calculation of a median half-life in the resting
BMDMs as described below.
2.6.5. Calculation of median transcript half-life in resting BMDMs
If the mean total RNA transcript abundance at the start of a 1 h
time interval is T0, the mean total RNA transcript abundance at the
end of the interval T1, the mean newly-transcribed RNA transcript
abundance N1 and the mean pre-existing RNA transcript abun-
dance P1, we should observe that N1/T1 + P1/T1 = 1. In practice,
however, we observed some systematic disagreement with this
equality. To maximise agreement, therefore, we introduced two
normalisation constants, a and b, and rewrote the above equation
as aN1/T1 + bP1/T1 = 1, as proposed in [39]. We then optimised a
and b by linear regression and used the constants obtained in the
calculation of half-lives for the time course. To estimate a half-life
value for every transcript detected by the microarrays in this
experiment, we calculated the values in two ways: (i) using newly
transcribed RNA transcript measurements (left equation) and (ii)
using the pre-existing RNA transcript measurements (right equa-
tion). A mean of the 2 values obtained from these equations was
then calculated.
t1=2 ¼ 55ln2
ln T1T0  a
N1
T0
  ; t1=2 ¼ 55ln2
ln b P1T0
 
In these calculations, we assumed a delay of 5 min before the
initiation of 4-thiouridine incorporation into newly synthesised
RNA. The resulting labelling period is, therefore, 55 min. Using
222 H. Lu et al. / Steroids 99 (2015) 219–229the above protocol, a median half-life value for the 5826 RNAs
detected in these experiments was estimated. This was subse-
quently used to assist in the normalisation of half-life data from
our time-course analysis of control treated or IFN-c treated
BMDMs (described in next section).
2.6.6. Estimation of transcript half-life in control or IFN-c BMDMs
From our time course experiments we obtained data from 1 h
intervals in which total and newly transcribed RNA had been anal-
ysed (150–210, 270–330, 330–390 and 390–450 min). This data
was used to estimate half-life values for Hmgcr transcript in the
control treated or IFN-c treated BMDM data. Since we had chosen
not to hybridise pre-existing RNA samples to microarrays in our 8-
h time course experiment, we used the formulae above to optimise
the value of a such that the median half-life across all transcripts in
the cintrol and IFN-c courses was the same as the value calculated
for the resting BMDMs. The output of these calculations provided
multiple, discrete half-life estimates for each transcript across
the 8-h control or IFN-c time course.
2.7. Software and statistical analysis
Microarray data analysis was performed by R [40]. The EC50 and
IC50 values were calculated by Matlab [41] and Graphpad
(GraphPad Software, Inc., La Jolla, CA, USA). Unpaired Student’s t
tests were performed by Graphpad. The half-life of Hmgcr mRNA
was calculated using Matlab. Adobe illustrator and Graphpad were
used to assemble ﬁgures.3. Results
3.1. Molecular circuitry for the rapid induction and inhibition kinetics
of de novo RNA synthesis of Ch25h and Atf3 by IFN in primary
macrophages.
In resting cells, latent transcription factors (named STATs)
associated with the IFN-receptor reside in the cytoplasm in an
inactive state and upon IFN binding its receptor, leads within sec-
onds, to phosphorylated active forms that translocates, within
minutes, to the nucleus, binding target promoters to transcription-
ally activate genes. Our previous studies have shown that IFN
activation of BMDMs results in the increased biosynthesis and
secretion of 25-HC as a result of a rapid STAT1 recruitment to
the promoter of the Ch25h gene within the ﬁrst hour of treatment
[30]. The Ch25h gene encodes an enzyme which is responsible for
catalysing the production of 25-HC from cholesterol. The timing
and duration of 25-HC synthesis have important implications for
its immune functions which are, in part, mediated through the
metabolic and immune modulatory re-programming of BMDMs
upon infection [42,23]. At the transcriptional level, ATF3 is a well
known transcriptional repressor for TLR driven pro-inﬂammatory
cytokines [43,44] including the induction of Ch25h [45]. ATF3 has
also been reported to be induced by TLR-IFN signalling [46–48]
and more recently has been found to repress the IFN-b promoter,
establishing a negative feedback loop [49]. A schematic summary
is shown in Fig. 6. While previous studies have clearly indicated
a rapid up-regulation of Ch25h expression in response to IFN, the
precise rate kinetics of IFN-c elicited Ch25hmRNA and Atf3 de novo
synthesis have not been determined. Furthermore, evidence for a
direct functional requirement of IFN signalling in TLR induction
of ATF3 in BMDMs has not been shown. Hence, our initial experi-
ments sought to quantitatively analyse de novo synthesis of
Ch25h mRNA and its negative regulator Atf3 in IFN-c stimulated
BMDMs and in BMDMs genetically ablated for the TLR-induction
of IFN-b.For these experiments, we performed an 8-h high-resolution,
systematic microarray analysis of changes in RNA synthesis, abun-
dance and decay in BMDM treated with 5 ng/mL IFN-c. Fig. 1a
shows how the de novo synthesis of Ch25h and Atf3 RNA altered
during this temporal analysis. Ch25h RNA synthesis rate was up-
regulated more than 4 fold in treated cells (relative to the control)
during the ﬁrst 30 min after the addition of the cytokine. Synthesis
of Ch25h RNA then peaked 60–90 min after treatment and was sub-
sequently down regulated, returning to basal transcriptional levels
by 210–240 min (Fig. 1a). The kinetics of the observed transcrip-
tional activation and repression provide an explanation for the
observed plateau by 8 h for the amount of intracellular and
secreted 25-HC as previously reported [30]. Notably, de novo syn-
thesis of Atf3 RNA, the product of which is a repressor of Ch25h
transcription, increased 60 min after the addition of IFN-c
(Fig. 1a). Atf3 RNA synthesis then peaked at 120 min, a time coinci-
dent with a marked reduction in Ch25h RNA synthesis. These
experiments show a rapidly initiated, but apparently tightly con-
trolled, transient up-regulation of Ch25h RNA synthesis during
the ﬁrst 4 h of IFN-c treatment in BMDMs.
Next, we examined whether the induction of Atf3 by TLR-
stimulation depends on the presence of an intact IFN-b-response
in BMDMs. For these experiments, wild-type or Ifnb/ BMDMs
were treated with the TLR-3 agonist, Poly (I:C) (10 lg/mL), and
the abundance of Irf1 (as a marker for STAT1 activation), Ch25h,
and Atf3 RNA was analysed at 2, 4, 6, 8 ,10 and 24 h after treatment.
Fig. 1b shows how overall RNA abundance of the interferon-regu-
lated gene Irf1 varied in our time-course. In wild-type BMDMs,
poly(I:C) treatment resulted in a rapid increase in Irf1 RNA abun-
dance during the ﬁrst 2 h of the time-course. Notably, between 2
and 8 h the abundance of this transcript remained elevated and
subsequently decreased from 10 h until 24 h. In Ifnb/ BMDMs,
in the absence of IFN-b production, the overall effect of the
Poly(I:C) stimulus was negated. Alterations in Ch25h transcript
expression elicited by Poly(I:C) followed a similar pattern to those
of Irf1 (Fig. 1c). This was expected as Stat1 regulates the transcrip-
tion of both genes in the context of IFN-b activation. After an initial
rapid increase of Ch25h RNA abundance, its RNA levels remained
elevated between 4 and 10 h and subsequently decreased by
24 h. In these experiments, increases in Ch25h RNA abundance
were not completely negated in the knockout BMDMs. This is likely
due to the activation of IFNAR1 by other type I interferons [24].
Most notably, Atf3-induced levels were ablated in Poly(I:C)-treated
Ifnb/ BMDMs (Fig. 1d). This demonstrates Atf3 has a strict depen-
dency on the IFN-b response for the transcriptional activation of its
promoter upon TLR stimulation. The molecular ‘‘wiring’’ for this
inﬂammatory regulatory circuit is shown in Fig. 6, which details
the stringent, coordinate control underpinning the regulation of
25-HC synthesis in IFN-activated BMDMs.
3.2. IFN-inducible-25-HC mediates a dose-dependent reduction of
HMGCR protein levels in BMDMs
We next sought to quantitatively determine proteomic parame-
ters for HMGCR inhibition that delineate the molecular circuitry for
the IFN-inducible 25-HC regulation of the sterol pathway. Whilst
the mechanism by which 25-HC regulates the SREBP pathway of
the sterol pathway has been extensively characterised (sum-
marised in Fig. 6), it is also known that 25-HC can post-translation-
ally regulate HMGCR protein abundance in a SREBP independent
manner [16,17]. We reasoned, therefore, that IFN-c treatment
might modulate the levels of Hmgcr mRNA and HMGCR protein
through SREBP-dependent and independent mechanisms, respec-
tively. To test this hypothesis, we quantiﬁed how increasing doses
of 25-HC alter HMGCR protein abundance in BMDMs. Under nor-
mal serum conditions, endogenous HMGCR protein levels are
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Fig. 1. Synthesis rates of de novo transcription of Atf3 and Ch25h following IFN-c treatment and RNA abundance of Irf1, Ch25h and Atf3 upon Poly (I:C) treatment. (a)
Measurement of de novo transcribed RNA of Atf3 and Ch25h upon IFN-c treatment in wild-type BMDMs (relative to control treated) in Medium A over an 8-h period. Each
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treatment. (d) Atf3 abundance in wild-type and Ifnb/ BMDMs (relative to control treated t = 0) in Medium A following 10 lg/mL Poly (I:C) treatment.
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tein levels can, however, be markedly increased upon cholesterol
depletion through compensatory homeostatic activity of the
SREBP-activated pathway. We ﬁrst quantiﬁed the HMGCR protein
level with various concentrations of mevastatin under lipid-deﬁ-
cient condition (Fig. 2a). The EC50 value for mevastatin-induced
increase of HMGCR levels in our experimental conditions was esti-
mated to be 0.03 lM (Fig. 2b). This estimate closely agrees with
published IC50 data for mevastatin inhibition of HMGCR enzymatic
activity (ranging from 0.01 to 0.11 lM) [50–53]. On the basis of
these results, we selected a low concentration of mevastatin
(0.01 lM), to allow for an increased dynamic range for measuring
levels of HMGCR. Note, under these conditions, the SREBP pathway
should be mildly activated. The effects of varying 25-HC dose on
HMGCR protein abundance in BMDMs were quantitated following
concurrent (Fig. 2c) or a 24-h pre-treatment (Fig. 2e) of the cells
with 0.01 lM mevastatin. IC50 values for 25-HC-induced reduction
of HMGCR under these experimental conditions were 0.04 lM
(Fig. 2d) and 0.02 lM (Fig. 2f). Taken together, these data show
that there is a dose-dependent decrease in levels of HMGCR protein
upon exposure of BMDMs to 25-HC.3.3. IFN-c exerts an immediate early SREBP-independent proteomic
layer of regulation of HMGCR followed by a delayed early SREBP-
dependent transcriptional mechanism
In our next experiments, we aimed to determine and compare
the extent of IFN induced reduction in HMGCR RNA levels (depen-
dent on the activity of the SREBP pathway) and protein levels
(which we assume involves a combination of SREBP-dependent
and SREBP-independent pathways). Time course experiments
measuring the reduction of total RNA of Hmgcr after 8 h of IFN
treatment revealed RNA abundance for this transcript decreased
by approximately 2 fold (Fig. 3a). In separate experiments, measur-
ing the de novo synthesis of RNA over an 8-h period, an approxi-
mately 2-fold reduction in the rate of RNA synthesis was also
observed (Fig. 3b). Marked changes in Hmgcr abundance and rates
of synthesis occur after approximately 200 min. To determine if
this is due to rate of transcription or stability of RNA transcript
changes we next computed the rates of RNA turnover of Hmgcr
RNA from 270 to 450 min in 60-min intervals. Fig. 3c shows there
is no statistical difference in the turnover rate. This indicates that
the approximately 50% reduction in RNA abundance by 8–9 h is
224 H. Lu et al. / Steroids 99 (2015) 219–229due to changes in the rates of transcription alone and the deter-
mined turnover rates (approximately 73 min) suggest at least an
hour response time to effect a change in abundance.
We next investigated the quantitative effects of direct 25-HC
administration (2.5 lM) to BMDMs on RNA and protein levels
under sterol-depleted conditions as discussed above. Consistent
with the data in Fig. 3a and b, a signiﬁcant reduction in RNA levels
was detected at 9 h post-treatment revealing a greater magnitude
of RNA reduction (approximately 45%) with only a small decre-
ment at 1.5 h (Fig. 3d). In contrast, levels of HMGCR protein were
more than 90% reduced by 1.5 h of 25-HC treatment and main-
tained a similar reduced level at 9-h post-treatment (Fig. 3e and
f). In summary, these experiments show that 25-HC rapidly dimin-
ishes macrophage HMGCR protein levels within the ﬁrst hour of
treatment. Note, at the later time point (9 h), reductions in RNAHMGCR
β-actin
Mevast
Concentrati
V 0.001 0.005 0.01 0.05 0.1 0.5
(a)
(c)
25-H
Concentrati
V 0.05
HMGCR
0Hours 24
0Hours 24
HarvestMevastatin
HarvestMevastatin+25-HC
0.001 0.01 0.1 0.50.005
β-actin
25-H
Concentrati
V 0.05
HMGCR
0Hours 24
Mevastatin+25-HC
0.001 0.01 0.1 0.50.005
β-actin
Mevastatin
(e)
Fig. 2. HMGCR protein levels following mevastatin and 25-HC treatments. (a) Western
Cells were treated overnight with various concentrations of mevastatin in Medium B. (b)
of mevastatin was then generated. Data are mean ± SEM (n = 3). (c) Western blot analysi
were treated with various concentrations of 25-HC for 24 h in Medium C. (d) Intensity v
was then generated. Data are mean ± SEM (n = 4). (e) Western blot analysis of the endo
treated with Medium C overnight and then treated with various concentrations of 25-
calculated, based on which the IC50 value of 25-HC was then generated. Data are meanlevels will also contribute, in an additive manner, to a sustained
reduction of HMGCR abundance.
We next quantiﬁed the RNA (Fig. 3g) and protein (Fig. 3h and i)
levels of HMGCR with IFN-c treatment at multiple time points.
These experiments were also performed using sterol-depleted con-
ditions. Fig. 3g–i shows that IFN-c treatment results in a 20%
decrease for both RNA and protein levels of HMGCR at 1.5-h
post-treatment. However, at 9-h post-treatment, the reduction in
RNA and protein levels is about 50% and 90%, respectively. These
results point towards both transcriptional and post-translational
mechanisms contributing to the maintenance of reduced HMGCR
levels at late times. These data provide evidence showing that
IFN-c and 25-HC can transcriptionally and post-translationally
alter levels of HMGCR. These differential modes of action are tem-
porally coordinated with rapid early effects on HMGCRmediated atatin 
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equal contributions at the protein and RNA levels.
3.4. IFN-c induces proteasomal degradation of HMGCR
It is well documented that 25-HC can promote the degradation
of HMGCR protein through an ubiquitin-proteasome system
[16,17]. We hypothesised, therefore, that IFN-c, acting throughan induction of 25-HC, can also promote the proteasomal degrada-
tion of HMGCR protein.
To test whether the reduction of HMGCR protein by IFN-c in
BMDMs involves proteasomal degradation, we utilised the protea-
some speciﬁc inhibitor, MG132 [16]. The results shown in Fig. 4a
and b demonstrate that MG132 treatment can inhibit the degrada-
tion of HMGCR induced by 25-HC as expected. Strikingly, 6 h of
IFN-c treatment in BMDMs also leads to a signiﬁcant reduction
226 H. Lu et al. / Steroids 99 (2015) 219–229in HMGCR levels (Fig. 4a and c) that is completely blocked by the
proteasome inhibitor, MG132. We conclude from these experi-
ments that 25-HC or IFN-c treatment leads to the proteasomal
degradation of HMGCR.
3.5. IFN-c-elicited reduction of HMGCR protein absolutely requires the
de novo synthesis of 25-HC
The experiments described above strongly suggest the possibil-
ity that IFN-c alters levels of HMGCR through de novo synthesis of
25-HC. To unequivocally test this possibility, we utilised BMDMs
derived from Ch25h/ mice. The genetic ablation of Ch25h results
in a complete inability of BMDMs from Ch25h/ mice to produce
25-HC [26]. We anticipated, therefore, that IFN-c would be unable
to reduce HMGCR abundance in these knockout cells. Accordingly,
Ch25h/ and wild-type BMDMs were treated with, 25-HC (as a
positive control) or, IFN-c and the levels of HMGCR protein were
quantiﬁed (Fig. 5a–d). As expected, both 25-HC and IFN-c treat-
ment of wild-type BMDMs lead to a greater than 90% decrease in
HMGCR protein levels by 9 h post treatment and which temporally
reﬂects both SREBP dependent and independent pathways.
However, at earlier times (4 h post-treatment), only a 50% reduc-
tion in HMGCR was observed for IFN-c treatment in contrast to
the nearly 100% reduction observed for 25-HC (Fig. 5a and b).
This level of reduction can not be accounted for by the SREBP path-
way alone because of the delineated 3–4 h lag period required forVe
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the 50% reduction at 4 h of IFN-c is mainly due to the SREBP-
independent pathway for targeted proteasomal degradation. In
Ch25h/ BMDMs, the reduction in levels of HMGCR by IFN-c treat-
ment at both 4 and 9 h were completely abrogated while 25-HC
was capable in mediating a decrease of HMGCR protein in these
cells at both time points (Fig. 5c and d). These experiments there-
fore provide direct evidence that the ﬁrst 9 h of IFN-c-activation
reductions in HMGCR protein abundance require the de novo syn-
thesis of 25-HC by Ch25h.
As the induction of CH25H is rapidly suppressed we anticipate
that the effective time for 25-HC may be limited to the ﬁrst 12–
24 h. Yet we have shown that in IFN activated BMDMs the inhibi-
tion of the sterol pathway is maintained for at least a period of 48–
72 h [24]. We therefore asked whether the synthesis of 25-HC is
also exclusively required for longer-term suppression of HMGCR.
Fig. 5e shows the results of experiments measuring Hmgcr RNA
levels in wild-type and Ch25h/ BMDMs treated with IFN-c or
25-HC for 24 h. In wild-type BMDMs, an expected 40-50% drop in
RNA levels is detected for 25-HC treatment while it is notable for
IFN-c treatment, Hmgcr levels are further decreased by 60–70%.
In Ch25h/ BMDMs, Hmgcr RNA levels are signiﬁcantly reduced
but statistically higher than the wild-type levels. As a control, in
Ch25h/ BMDMs 25-HC treatment retains a similar level of inhibi-
tion of Hmgcr RNA. Therefore, these results demonstrate that while
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mediated at the RNA level is only partially (approximately 50%)
dependent on this oxysterol.3.6. A model for the regulatory control of HMGCR by IFN
The above experiments suggest a complex multi-layered reg-
ulatory pathway by which IFN-c suppresses HMGCR. We have
demonstrated that IFN-c can transcriptionally and post-
translationally regulate HMGCR, mediated through the de novo
synthesis of 25-HC. Altogether, our results provide a foundation
for further understanding of the complex regulation of the sterol
biosynthesis pathway by the immune system through com-
putational modelling. Toward this endeavour, Fig. 6 provides a
graphical model for the coordinate regulation of HMGCR by IFN-
c, constructed using the systems biology graphical notation
(SBGN) [54]. Speciﬁcally, IFN transcriptionally increases the
expression of Ch25h expression via STAT1 , whose translational
product catalyses the production of 25-HC. The newly synthesised
25-HC can rapidly promote the proteasomal degradation ofHMGCR and retain SREBP2 in the ER, which suppresses the tran-
scription of Hmgcr and with concomitant temporal delay in trans-
lation further reduces HMGCR. The induction of Ch25h is curtailed
by the repressor ATF3 that also negatively feedback on the IFN
response. Therefore, IFN via CH25H regulates both the Hmgcr
mRNA and HMGCR protein levels within the ﬁrst 9 h of treatment
through 25-HC mediated SREBP dependent and independent
pathways.4. Discussion
In this study we quantitatively elucidate how IFN-c regulates
the mevalonate-sterol pathway by targeting HMGCR through both
SREBP-dependent and independent pathways. We show that in
BMDMs, IFN-c elicits a rapid proteasomal degradation of HMGCR.
Importantly, the effects of this degradation are later potentiated
through transcriptional and translational repression of HMGCR.
Further, we demonstrate that IFN-c mediates this effect through
the de novo induction of CH25H expression and subsequent syn-
thesis of 25-HC. This work provides, therefore, a foundational
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insights into IFN-c mediated macrophage suppression of meval-
onate-sterol biosynthesis and the anti-viral response.
The mevalonate-sterol biosynthesis pathway is active in all cells
of the body and is responsible for the production of cholesterol,
isoprenoids, ubiquinone and downstream metabolites of oxys-
terols and steroid hormones. These products are involved in a
range of core biological processes necessary for cell growth, meta-
bolic and oxidative homeostasis, membrane integrity, vesicular
transport and endocrine physiology. In addition, infectious agents,
such as microbial, parasitic, and especially viruses, also rely on
biosynthetic cellular pathways for their growth [55]. A common
feature of many unrelated pathogens is a dependency on cellular
lipid metabolism and we, and others, have shown that pharmaco-
logical inhibition of the mevalonate-sterol biosynthesis pathway,
in particular, can curtail pathogen growth [32,33,24,34].
Increasingly, studies are emerging that the immune system and
lipid pathways are tightly coupled. Notably, both upstream and
downstream metabolites of this pathway are known to play key
roles in immunity and likely explain its long standing association
with inﬂammatory based diseases such as atherosclerosis.
Deﬁning how immunity and lipid metabolism are integrated, share
resources and cross-regulate one-another during infection is,
therefore, of great importance to our understanding of anti-infec-
tive immunity and the development of new therapeutic strategies.
Recently, we identiﬁed an interferon-induced reduction in
sterol biosynthesis as a key component of the very early cellular
response to virus-infection in BMDMs [24]. This led to a focus on
characterising the close coupling between interferon and meval-
onate-sterol metabolism and to the identiﬁcation of 25-HC biosyn-
thesis as an important component of the interferon-induced anti-
viral response in BMDMs [42,24,31]. For over 40 years, 25-HC
was recognised to have a potent ability to negatively feedback on
the regulation of cholesterol biosynthesis [56]. However, it is only
in the last half decade that a physiological role of 25-HC associated
with immune-related functions has emerged. These have included
the TLR activation of its production in BMDMs and DCs [29], the
regulation of immunoglobulin A production [26], as an effector of
IFN-response mediating potent cell-autonomous anti-viral immu-
nity in BMDMs [24,31], functional requirement as an immune B-
cell guidance cue for adaptive immunity and roles in pro- andanti-inﬂammatory cytokine production [28,27]. Hence, it is now
clear that a key physiological function of 25-HC is as a central
effector of immune homeostasis and response to infection.
Our previous studies have shown that 25-HC biosynthesis is
regulated by IFN-induced STAT1 binding to the CH25H promoter
and, is accordingly dramatically up-regulated in BMDMs in the ﬁrst
hour after infection or IFN activation. Notably, we found that
through SREBP-dependent and independent mechanisms, 25-HC
can inhibit, in a cell-autonomous manner, a wide range of viruses.
The principal pathway for anti-viral activity mediated by 25-HC for
a number of viruses consistently maps to the proximal mevalonate
arm of the pathway. Importantly, HMGCR represents the ﬁrst reg-
ulatory enzymatic step in this part of the sterol pathway and sta-
tins or interference RNA inhibition of HMGCR markedly inhibit
viral growth. The role of 25-HC anti-viral pathway in vivo requires
further investigation.
Howprecisely IFN controls the sterol pathway is little understood.
Here, in our detailed kinetic and quantitative investigations, to fur-
ther explore the IFN regulation of sterol biosynthesis, we systemati-
cally uncovered evidence that demonstrates a direct coupling
between IFN-c signalling and the synthesis of 25-HC that mecha-
nistically involves a temporal, multi-layered suppression of the
mevalonate arm of the sterol biosynthesis pathway. Within the ﬁrst
90–200 min of IFN-c stimulation of BMDMs, HMGCR is directed by
25-HC for proteasomal degradation and is coordinately sustained
for reduced expression through blockade of the restorative SREBP
pathway, suppressing both RNA and protein synthesis (Fig. 6).
Thus, our ﬁndings provide a foundation and framework for future
modelling and predictive therapeutic intervention strategies for
regulating sterol biosynthesis and its immune effector functions.
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